Anoro Ellipta is a Respiratory (inhalation) Powder in the Human Prescription Drug category. It is labeled and distributed by Glaxosmithkline Llc. The primary component is Umeclidinium Bromide; Vilanterol Trifenatate.
| Product ID | 0173-0869_0da3b67c-1baa-4cd2-b7af-f7a969b1040b |
| NDC | 0173-0869 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Anoro Ellipta |
| Generic Name | Umeclidinium Bromide And Vilanterol Trifenatate |
| Dosage Form | Powder |
| Route of Administration | RESPIRATORY (INHALATION) |
| Marketing Start Date | 2014-01-31 |
| Marketing Category | NDA / NDA |
| Application Number | NDA203975 |
| Labeler Name | GlaxoSmithKline LLC |
| Substance Name | UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE |
| Active Ingredient Strength | 63 ug/1; ug/1 |
| Pharm Classes | Anticholinergic [EPC],Cholinergic Antagonists [MoA],Adrenergic beta2-Agonists [MoA],beta2-Adrenergic Agonist [EPC] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2020-12-31 |
| Marketing Start Date | 2014-01-31 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA203975 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2014-01-31 |
| Marketing Category | NDA |
| Application Number | NDA203975 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2014-01-31 |
| Marketing Category | NDA |
| Application Number | NDA203975 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2014-01-31 |
| Ingredient | Strength |
|---|---|
| UMECLIDINIUM BROMIDE | 62.5 ug/1 |
| SPL SET ID: | 2dbd0671-c565-40c5-bf0f-e324db26799c |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() ANORO ELLIPTA 85831335 4552628 Live/Registered |
Glaxo Group Limited 2013-01-24 |
![]() ANORO ELLIPTA 85727843 not registered Dead/Abandoned |
Glaxo Group Limited 2012-09-13 |